Interaction of polymorphisms in resistin gene promoter -420C/G, cytochromes P4501A1 gene MspI and cigarette smoking on nonalcoholic fatty liver disease
ZHANG Chao-xian1, GUO Li-ke2
1. Department of Gastroenterology, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China;
2. Depatment of Stomatology, The First Affiliated Hospital of Xinxiang Medical University, Weihui 453100, China
AIM: To investigate the interaction of polymorphisms of resistin gene promoter -420C/G, cytochromes P4501A1-MspI and cigarette smoking in nonalcoholic fatty liver disease (NAFLD). METHODS: The genetic polymorphisms in resistin gene promoter -420C/G and CYP1A1-MspI were analyzed by the technique of polymerase chain reaction (PCR) in peripheral blood leukocytes of 900 NAFLD cases and 900 healthy persons. RESULTS: The frequencies of -420C/G (GG) and CYP1A1-MspI (m2/m2) were 49.75% and 50.08% in NAFLD cases and 24.00% and 24.25% in healthy controls, respectively. Statistical tests showed a significant difference in the frequencies between the 2 groups (P<0.01). The risk of NAFLD with -420C/G (GG) was significantly higher than that of controls. Individuals who carried with CYP1A1-MspI (m2/m2) had a high risk of NAFLD. Combined analysis of the polymorphisms showed that the percentages of -420C/G (GG)/CYP1A1-MspI (m2/m2) in NAFLD and control groups were 39.83% and 12.83%, respectively (P<0.01). The people who carried with -420C/G (GG)/CYP1A1-MspI(m2/m2) had a high risk in NAFLD group. The cigarette smoking rate in NAFLD group was signi-ficantly higher than that in control group (P<0.01), and the statistic analysis suggested an interaction between cigarette smoking and -420C/G (GG) and CYP1A1-MspI (m2/m2), which increased the risk of NAFLD.CONCLUSION: -420C/G (GG), CYP1A1-MspI (m2/m2) and cigarette smoking are the risk factors in NAFLD. The interactions between genetic polymorphisms in -420C/G, CYP1A1- MspI (m2/m2) and cigarette smoking increase the risk of NAFLD.
do Nascimento JH, Epifanio M, Soder RB, et al. MRI-diagnosed nonalcoholic fatty liver disease is correlated to insulin resistance in adolescents[J]. Acad Radiol, 2013, 20(11):1436-1442.
[2]
Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease[J]. J Nutr Biochem, 2012, 23(3):203-208.
Liu Y, Dai M, Bi Y, et al. Active smoking, passive smoking, and risk of nonalcoholic fatty liver disease (NAFLD): a population-based study in China[J]. J Epidemiol, 2013, 23(2):115-121.
[6]
Boyraz M, Cekmez F, Karaoglu A, et al. Serum adiponectin, leptin, resistin and RBP4 levels in obese and metabolic syndrome children with nonalcoholic fatty liver disease[J]. Biomark Med, 2013, 7(5):737-745.
Zhang LY, Jin YJ, Jin QS,et al. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus[J]. Gene, 2013, 529(2):340-344.
[10]
Jiang W, Wang L, Kondraganti SR, et al. Disruption of the gene for CYP1A2,which is expressed primarily in liver, leads to differential regulation of hepaticand pulmonary mouse CYP1A1 expression and augmented human CYP1A1 transcriptional activation in response to 3-methylcholanthrene in vivo[J]. J Pharmacol Exp Ther, 2010, 335(2):369-379.
Hossein-Nezhad A, Varzaneh FN, Mirzaei K, et al. A polymorphism in the resistin gene promoter and the risk of multiple sclerosis[J]. Minerva Med, 2013, 104(4):431-438.
[13]
Tan C, Xu HY, Zhang CY, et al. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer[J]. Arch Med Res, 2011, 42(8):669-676.
[14]
Khoury MJ, Wagener DK. Epidemiological evaluation of the use of genetics to improve the predictive value of disease risk factors[J]. Am J Hum Genet, 1995, 56(4):835-844.
[15]
Lebensztejn DM, Wojtkowska M, Skiba E, et al. Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease [J]. Adv Med Sci, 2009, 54(2):177-182.
Boumaiza I, Omezzine A, Rejeb J, et al. Association between four resistin polymorphisms, obesity, and metabolic syndrome parameters in Tunisian volunteers [J]. Genet Test Mol Biomarkers, 2012, 16(12):1356-1362.
[19]
Bik W, Ostrowski J, Baranowska-Bik A, et al. Adipokines and genetic factors in overweight or obese but metabolically healthy Polish women[J]. Neuro Endocrinol Lett, 2010, 31(4):497-506.
[20]
Norata GD, Ongari M, Garlaschelli K, et al. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction[J]. J Intern Med, 2007, 262(1):104-112.
Sharma KL, Agarwal A, Misra S, et al. Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility[J]. Tumour Biol, 2014, 35(6):5431-5439.
[23]
Li W, Song LQ, Tan J. Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis[J]. Tumour Biol, 2014, 35(9):9281-9290.
[24]
Sergentanis TN, Economopoulos KP, Choussein S, et al. Cytochrome P450 1A1 (CYP1A1) gene polymorphisms and cervical cancer risk: a meta-analysis[J]. Mol Biol Rep, 2012, 39(6):6647-6654.
[25]
Jia WP. The impact of cigarette smoking on metabolic syndrome[J]. Biomed Environ Sci, 2013, 26(12):947-952.
[26]
Yalcinkaya E, Celik M, Gursoy E. Determining the combined effects of smoking and obesity on insulin resistance and inflammation[J]. Eur Rev Med Pharmacol Sci, 2014,18(5):760.
